P17.83 OUTCOMES OF RECURRENT GLIOBLASTOMA PATIENTS TREATED WITH BEVACIZUMAB AT A TERTIARY CARE CENTER

BACKGROUND: Bevacizumab is FDA approved for use in recurrent glioblastoma (rGBM). There is limited information on outcomes of rGBM treated with bevacizumab at tertiary care hospitals. We evaluated the progression-free survival (PFS) and overall survival (OS) in rGBM patients treated with bevacizumab...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Stevens, G.H.J., Sakruti, S., Griffin, S., Peereboom, D., Ahluwalia, M.S.
Format: Artigo
Sprache:Inglês
Veröffentlicht: Oxford University Press 2014
Schlagworte:
Poster Presentations
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4185786/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nou174.412
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge